Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

Axonyx Inc. (AXYX)

Serono AS (Switzerland; NYSE:SRA)

up to $22.5

Serono exercised its option from their 1999 agreement, gaining exclusive rights to Axonyx's amyloid and prion inhibitory peptides for drug development in the diagnosis and treatment of Alzheimer's and other neurodegenerative disorders; Axonyx will receive an initial payment of $1.5M and future payments of up to $21M as drug development milestones are met, plus royalties on any commercialized products

Biobase Biological Databases GmbH (Germany)

Eli Lilly and Co. (NYSE:LLY) and Schering-Plough Research Institute

ND

Schering and Eli Lilly licensed the Transfac Professional database from Biobase, gaining access to annotated information for gene transcription regulation

BioSignal Packard Inc. (subsidiary of Packard Bioscience Co.; PBSC)

AstraZeneca R&D Montreal (subsidiary of AstraZeneca; UK; NYSE:AZN)

$5.5

BioSignal was awarded a greatly expanded screening contract for the use of BioSignal's technologies to test AstraZeneca's combinatorial compound libraries against a defined selection of G protein-coupled receptors; this agreement follows a three-year contract which ended 9/00

Cetek Corp.

Taisho Pharmaceutical Co. Ltd. (Japan)

ND

Taisho will utilize Cetek's proprietary, capillary electrophoresis technology in screening its targets; Cetek will develop assays for Taisho's targets and screen against Taisho's libraries

ChemBridge Corp.

AstraZeneca (UK; NYSE:AZN)

ND

AstraZeneca gains nonexclusive access to ChemBridge's PHARMACore combinatorial lead discovery library; this agreement is another in a series of combinatorial library agreements between the companies in the past 12 months

Chiron Corp. (CHIR)

F. Hoffmann-La Roche (Switzerland)

ND

Roche receives a broad patent license for probe-based clinical diagnostics for the hepatitis C virus and HIV, settling their litigation in the U.S. and six other major markets in clinical diagnostics; Chiron will receive up-front payments representing royalties for past-HCV sales and prepayment of certain HCV royalties; it also provides for Chiron to receive contingent milestone payments

CollaGenex Pharmaceuticals Inc. (CGPI)

ISDIN SA (Spain)

ND

ISDIN received rights to market and distribute Periostat in Greece; ISDIN will purchase Periostat from CollaGenex's UK subsidiary, CollaGenex International Ltd.; financial terms were not disclosed

Connetics Corp. (CNCT)

ALZA Corp. (NYSE:AZA)

ND

The companies entered into an agreement to develop an advanced drug delivery system for Connetics' proprietary recombinant human relaxin drug candidate; the development will focus on applying ALZA's implantable delivery technology, the DUROS system, to expand delivery options for relaxin, a naturally occurring hormone with a broad spectrum of biological activities

Cortex Pharmaceuticals Inc. (OTC BB:CORX)

Les Laboratoires Servier (France)

$5

Servier receives an exclusive license to develop and commercialize Cortex's Ampakine technology for the treatment of declines in cognitive performance associated with aging and neurodegenerative diseases

Cortex Pharmaceuticals Inc. (OTC BB:CORX)

Les Laboratoires Servier (France)

$2

Cortex and Servier will jointly research and clinically develop new Ampakines for Alzheimer's disease, mild cognitive impairment, sexual dysfunction and dementias associated with multiple sclerosis and Lou Gehrig's disease; Cortex will receive the money for a minimum of three years in research support

Cortex Pharmaceuticals Inc. (OTC BB:CORX)

Les Laboratoires Servier (France)

ND

The companies will conduct a mild cognitive impairment (MCI) study to determine the efficacy of the Ampakine CX516 in improving memory and cognition in MCI; Cortex will supply bulk CX516 for the cross-national MCI trial; both companies will share in the clinical trial costs

diaDexus Inc.

Agilent Technologies Inc. (NYSE:A)

ND

diaDexus obtained access to Agilent's customizable microarray technology for research into the molecular basis for cancer and other diseases; financial details were not disclosed

Discovery Partners International Inc. (DPII)

Procter & Gamble (NYSE:PG)

ND

ChemRx Advanced Technologies, a division of Discovery, will provide purified diverse compounds over a three-year period for pharmaceutical screening for Procter & Gamble, with the option of providing hit follow-up and lead optimization; financial terms of the deal were not disclosed

Diversa Corp. (DVSA)

Novartis Agribusiness Biotechnology Research Inc.

ND

The companies expanded their collaboration agreement, using Diversa's proprietary evolution technologies to further develop and optimize novel synthesis routes for crop protection chemicals; Diversa will receive research payments, milestones and product royalties

DoubleTwist Inc.

Hitachi Ltd. (Japan)

ND

Hitachi licensed DoubleTwist's suite of bioinformatics software, DoubleTwist.com and Prophecy, for marketing and distribution in the Asia-Pacific region; Hitachi will provide the bioinformatics services via a virtual private network

Ecopia BioSciences (Canada)

Merck & CO. Inc. (NYSE:MRK)

$0.125

The companies entered into a 12-month research agreement; terms and targets were not disclosed

Entelos Inc.

Bayer AG (Germany; DAX:BAY)

ND

Entelos completed an engagement with Bayer AG to evaluate an interleukin-4 receptor antagonist as a potential treatment for asthmatics

Exelixis Inc. (EXEL)

Genoptera LLC (subsidiary of Bayer AG; Germany; DAX:BAY)

ND

A joint venture, with Exelixis delivering two assays to identify novel classes of safe and effective insecticides for high-throughput screening to Bayer, which would trigger milestone payments to Exelixis

Gene Logic (GLGC)

UCB Pharma (Belgium)

ND

UCB Research, a division of UCB Pharma, expanded its partnership with Gene Logic and added a multi-year subscription to a segment of Gene Logic's GeneExpress Suite of databases; the Atlas DataSuite will be used for development of custom gene expression database for new drug discovery focused on allergy; financial terms were not disclosed

GeneData AG (Switzerland)

Schering AG (Germany)

ND

Companies expanded their collaboration to improve target-finding and diagnostic capabilities of expression arrays, entering into a multi-year licensing agreement to use GD Expressionist for analysis of gene expression array data

Geneva Proteomics Inc.

Novartis Pharma AG (Switzerland)

$84

The companies formed an alliance to discover novel therapeutics, targets and biomarkers; Novartis will make a total equity investment of $43M and will become Geneva's preferred pharmaceutical partner, also paying defined proteome fees of $41M over four years; further license fees, milestone payments and reimbursements are possible; Novartis will gain exclusivity for three years or more for several hundred molecules and information on expression patterns studied in the alliance

Genometrix Inc.

Schering-Plough Corp. (NYSE:SGP)

ND

Genometrix signed an agreement with Schering-Plough Research Institute, allowing SPRI to access the GenoVista Partnership Program, making available Genometrix's high-throughput sample analysis services using customized VistaArray microarrays for genotyping and gene expression applications and the VistaLogic Information System

Genzyme Molecular Oncology (GZMO)

Purdue Pharma L.P. (subsidiary of Purdue Pharma)

$330

Under the three-year research program, Purdue will select up to 20 cancer antigens identified by Genzyme; both may commercialize products using those selected antigens; any identified antigens not selected by Purdue will remain the property of Genzyme; Genzyme will receive over $21M in technology access fees, research funding and an equity investment, and up to $310M in milestones, as well as royalties

Hemosol Inc. (Canada; TSE:HML)

Baxter Biotech S.a.r.l. (subsidiary of Baxter Healthcare Corp.; NYSE:BAX)

ND

The agreement allows Hemosol to purchase worldwide patents and intellectual property related to drug delivery technology; Hemosol will make cash payments to Baxter on a progressive basis, along with a 4% royalty on commercialized products

Human Genome Sciences Inc. (HGSI)

Aventis Behring L.L.C. (unit of Aventis SA; NYSE:AVE)

ND

The companies entered into a joint development and commercialization agreement to co-develop and jointly market an Aventis Behring plasma protein product, using HGS' acquired Principia Pharmaceutical Corp. fusion technology to create a plasma protein-albumin fusion therapeutic

Human Genome Sciences Inc. (HGSI)

Dow Chemical Company (NYSE:DOW)

ND

Agreement to develop a radiolabeled drug for treatment of B-cell malignancies using Dow's bifunctional chelation agent with HGS' B-lymphocyte stimulator protein

Human Genome Sciences Inc. (HGSI)

Schering-Plough Corp. (NYSE:SGP)

ND

Schering exercised one of its product option rights from their 1996 therapeutic collaboration and license agreement to develop and commercialize a novel type of interferon discovered by HGS, paying clinical development milestones and royalties to HGS

Human Genome Sciences Inc. (HGSI)

SmithKline Beecham Corp. (UK; LSE:SB)

ND

SmithKline exercised its first co-right option to jointly develop and commercialize repifermin (keratinocyte growth factor-2), a therapeutic with application in wound care; both parties will share equally in clinical development costs at Phase III and beyond

IGEN International Inc. (IGEN)

Sumitomo Corp. (Japan)

$15.4

Companies signed a five-year non-exclusive agreement for Sumitomo's subsidiary SC BioSciences Corp. to distribute IGEN's M-Series M8 biological detection system in Japan's life science market; SC will purchase a minimum of $15.4M of instruments; IGEN and its Japanese subsidiary, IGEN KK, will market and sell all consumable reagents and assays for these instruments in Japan; SC BioSciences will provide support and services to facilitate that effort

Incyte Genomics Inc. (INCY)

American Home Products (NYSE:AHP)

ND

Incyte licensed U.S. Patent numbers 5,716,785 and 5,891,636, and related patents, to AHP for internal use in creating gene expression data with Affymetrix GeneChips arrays; financial terms were not disclosed

Incyte Genomics Inc. (INCY)

Bristol-Myers Squibb Co. (NYSE:BMY)

ND

Bristol-Myers will license Incyte's LifeExpress gene expression database; Incyte could receive future milestone payments and royalties; financial terms were not disclosed

Incyte Genomics Inc. (INCY)

PerkinElmer Life Sciences (NYSE:PKI)

ND

Incyte granted access to its collection of proprietary cDNA clones from LifeSeq Gold to NEN Life Science Products, a part of PerkinElmer; Incyte will receive royalties on sales on NEN microarrays developed using Incyte technology; financial terms were not disclosed

Isis Pharmaceuticals Inc. (ISIP)

Roche Molecular Systems Inc. (unit of Roche Diagnostics)

ND

Isis will provide a non-exclusive license of novel chemistry patents to Roche for use in Roche's production of diagnostic products; Roche will gain worldwide access to proprietary Isis chemistry in exchange for initial and ongoing payments

Karo Bio (subsidiary of Karo Bio AB; Sweden; SSE:KARO)

Aventis Pharma (subsidiary of Aventis SA; France; NYSE:AVE)

$32

Karo will provide Aventis with access to its BioKey drug discovery technology for infectious disease targets identified through Aventis' genomics programs; Aventis has an option to extend the initial one-year term for three additional years; financial terms, excluding royalty income, can exceed the disclosed value, assuming the development and approval of two compounds

Karo Bio AB (Sweden; SSE:KARO)

Merck & Co. Inc. (NYSE:MRK)

ND

Extension of 1997 collaboration for the development of novel therapies treating diseases targeting human estrogen receptors and extending to a range of other diseases

LactoFerrin Products Co.

Mannatech Inc.

ND

Mannatech was granted exclusive worldwide distribution rights to a patent-pending combination of immune-supporting ingredients that include Prime Colostrum in a mucosal delivery format

Lexicon Genetics Inc. (LEXG)

Bristol-Myers Squibb Co. (NYSE:BMY)

ND

Bristol-Myers was granted a non-exclusive sub-license for use of parts of Lexicon's positive-negative selection and isogenic DNA technologies to identify valid drug targets or therapeutic proteins; financial terms were not disclosed

Lion Bioscience AG (Germany; LEON, Neuer Markt:LIO) and Tripos Inc. (TRPS)

Bayer AG (Germany; DAX:BAY)

$25

Lion and Tripos expanded their partnership, providing Bayer with an integrated cheminformatics technology platform to speed Bayer's identification of lead candidates for its drug and agricultural chemical programs; both partners will share the total payments, including an up-front payment, technology license fee, R&D funding and milestone payments, and will retain all rights for the immediate resale of software systems and solutions developed

MacroChem Corp. (MCHM)

Pfizer Inc. (NYSE:PFE)

ND

Pfizer will evaluate the feasibility of using MacroChem's patented topical absorption enhancer SEPA to improve skin absorption of a group of Pfizer pharmaceuticals

Myriad Genetics Inc. (MYGN)

MDS Inc. (Canada; NYSE:MDZ; TSE:MDS)

ND

MDS, Myriad's exclusive marketing partner for hereditary breast and ovarian cancer predictive testing in Canada, will now market Myriad's Colaris colon cancer predictive medicine product in Canada

Nortran Pharmaceuticals Inc.

AstraZeneca (UK; NYSE:AZN)

ND

AstraZeneca was granted an exclusive worldwide license to develop and market an undisclosed novel anti-arrhythmic drug candidate in exchange for up-front, milestone, and royalty payments; AstraZeneca will pay for all development and marketing costs

Orchid BioSciences Inc. (ORCH)

Eli Lilly and Co. (NYSE:LLY)

ND

Lilly will provide commercial single nucleotide polymorphism genotypes to Orchid to perform high-throughput SNP scoring

OrthoLogic Corp.

Sanofi-Synthelabo Inc. (U.S. subsidiary of Sanofi-Synthelabo; France)

ND

Sanofi reacquired the rights to market Hyalgan to the U.S. orthopedics market that had been granted to OrthoLogic under a 1997 agreement; no financial terms were disclosed

PPGx Inc.

Bristol-Myers Squibb Co. (NYSE:BMY)

ND

Bristol-Myers will incorporate PPGx's GeneTrials bioinformatics platform into its pharmacogenomics R&D program

Proteome Inc.

Janssen Research Foundation and R.W. Johnson Pharmaceutical Research Institute (units of Johnson & Johnson; NYSE:JNJ)

ND

Proteome expanded its subscription agreement with Janssen and PRI, including access to Proteome's databases for human genome research, the Human Proteome Survey Database and the G Protein-Coupled Receptor Proteome Database; JRF and PRI will continue to access Proteome's model organism databases and are the first to obtain access to the full BioKnowledge library

Synaptic Pharmaceutical Corp. (SNAP)

The R.W. Johnson Pharmaceutical Research Institute (unit  of Johnson & Johnson; NYSE:JNJ)

ND

PRI was granted non-exclusive licenses to Synaptic's alpha-1 adrenergic receptors and benign prostatic hypertrophy patents for use in all therapeutic indications; PRI will pay an up-front licensing fee, milestone payments and royalties to Synapatic; financial details were not disclosed

Techniclone Corp. (TCLN)

Merck KGaA (Germany)

ND

Merck received the right to use Techniclone's tumor necrosis therapy technology antibodies for producing immunocytokines; agreement involves and undisclosed up-front payment and royalty upon commencement of commercial sales

Therion Biologics Corp.

Aventis Pasteur Ltd. (Canada)

ND

Expanding the length and scope of their existing collaboration, the companies will study additional tumor-associated antigens for use in pox virus-based vaccines for the treatment of melanoma, colorectal and lung cancers; Therion receives new license payments, including additional milestones and potential royalties; Aventis acquires a worldwide sublicense to NY-ESO-1, a tumor-associated antigen

Trega Biosciences Inc. (TRGA)

Janssen Research Foundation and R.W. Johnson Pharmaceutical Research Institute (units of Johnson & Johnson; NYSE:JNJ)

ND

Expanding its relationship, Trega will provide a multi-year worldwide license, including all upgrades and enhancements, of its first two iDEA predictive modules simulating how drug candidates are absorbed and metabolized in the body

ViroLogic Inc. (VLGC)

F. Hoffmann-La Roche Ltd. (Switzerland)

ND

ViroLogic will use its drug resistance technology and phenotypic drug susceptibility test PhenoSenseHIV, to provide drug- resistance testing services in the Phase III clinical program involving the investigational anti-HIV drug T-20, which is being co-developed by Roche and Trimeris Inc.

VistaGen Inc.

Pfizer Inc. (NYSE:PFE)

ND

The companies entered into a joint development and evaluation of VistaGen's mouse-derived, stem cell-based Genesis Screen technology as a tool for clinically predictive toxicology screening assays; financial terms were not disclosed

Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

Affymetrix Inc. (AFFX)

Takara Shuzo Co. Ltd. (Japan)

ND

Takara gains a non-exclusive worldwide license under Affymetrix's intellectual property covering low- and medium-density DNA arrays; license covers technology used in Takara's Intelligene chips; Affymetrix received an up-front fee and will receive royalties

ArQule Inc. (ARQL)

The R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson; NYSE:JNJ)

ND

Companies amended 1998 collaboration to include access to ArQule's Compass Array libraries for J&J companies

Array BioPharma Inc.

Merck & Co. Inc. (NYSE:MRK)

ND

Expansion of existing collaboration to design and synthesize lead generation libraries for Merck

Atugen AG (Germany)

Bayer AG (Germany)

ND

Atugen will perform gene target validation services for Bayer

Aurora Biosciences (ABSC)

Merck & Co. (NYSE:MRK)

ND

Aurora and Merck will collaborate to discover novel ion channel modulation targets

Aurora Biosciences Corp. (ABSC)

Pfizer Inc. (NYSE:PFE)

ND

Aurora granted Pfizer a non-exclusive license to its Vivid technology, for determining whether compounds interact with key metabolic enzymes; Aurora will receive annual license fees and payments for reagents over several years

Cambridge Antibody Technology plc (UK; LSE:CAT)

Wyeth-Ayerst Research (unit of American Home Products Corp.; NYSE:AHP)

ND

Wyeth-Ayerst gained an exclusive license to develop products specific for the amyloid beta peptide implicated in Alzheimer's disease; the deal is a follow-on to the companies 3/99 agreement; CAT will receive a license fee and potential milestones and royalties

ChemDiv Inc.

Bristol-Myers Squibb Co. (NYSE:BMY)

ND

ChemDiv will give Bristol-Meyers access to CombiLab, the company's combinatorial librarie of small molecules

Corixa Corp. (CRXA)

Purdue Pharma L.P.

ND

Corixa and Purdue will develop up to four therapeutic antibodies based on Corixa-identified tumor antigens. Purdue provides Corixa with guaranteed research funding and may license resultant antibodies or targets from Corixa for upfront fees, milestones and royalties

Coulter Pharmaceutical Inc. (CLTR)

Kyowa Hakko Kogyo Co. Ltd. (Japan)

ND

Coulter licensed two anti-cancer compounds to inhance using its tumor activated prodrug (TAP) technology; the deal includes an upfront payment, milestones and royalties

De Novo Pharmaceuticals Inc.

Aventis Pharmaceuticals (NYSE:AVE)

ND

Aventis pays a technology access fee and provides research funding for a year for De Novo to use its algorithms to provide novel patentable small molecule leads

Deltagen Inc. (DGEN)

Glaxo Wellcome plc (UK; NYSE:GLX)

ND

Glaxo gains access to the DeltaBase gene function database and DeltaSelect drug target validation programs; Glaxo will pay a subscription fee of $5M per year over three years, plus discovery and development milestones and access fees

Dyax Corp. (DYAX)

Unilever Nederland B.V. (the Netherlands)

ND

Dyax acquired worldwide patent rights, including two newly issued U.S. patents (Nos. 6,114,147 and 6,027,910) covering yeast display technology; the license is exclusive in the field of therapeutics

EPIcyte Pharmaceutical Inc.

The Dow Chemical Co. (NYSE:DOW)

ND

Companies are collaborating to develop antibody-based products using EPIcyte's Plantibodies technology; agreement includes research program for optimizing antibody stability in plants and a manufacturing progrma to develop optimal processing for recovery and purification; Dow will manufacture at least five products for human health

EraGen Biosciences Inc.

Bayer Diagnostics

ND

EraGen licensed AEGIS synthetic base pair technology to Bayer

Generex Biotechnology Corp. (GNBT)

Eli Lilly and Co. (NYSE:LLY)

ND

Companies will use Generx technology to develop a buccal formulation of insulin administered as a fine spray into the oral cavity; Generx will receive initial fees and milestones, plus royalties on sales; Lilly will receive exclusive worldwide rights to products

GLYCODesign Inc. (Canada)

Seikagaku Corp. (Japan)

C$25 (US$16.9)

Companies expanded collaborative agreement begun 11/99 to identify small-molecule, orally active Core 2 transferase inhibitors displaying anti-inflammatory activity; new agreement expands indications to include cardiovascular diseases; GLYCODesign could receive C$25M (US$16.9M) if Seikagaku exercises all of the options available

Ilex Oncology (ILXO)

BASF Pharma (Germany)

ND

Companies completed a first agreement for an exclusive, worldwide license to BSF 223651, a promising anticancer compound; companies are finalizing an agreement giving Ilex an option for an exclusive worldwide license to Elinafide, another anticancer compound discovered by BASF; discussions are under way for additional BASF compounds

ImClone Systems Inc. (IMCL)

Lonza Biologics (Switzerland)

ND

Lonza will be a second-source manufacturer of ImClone's IMC-C225 cancer drug

Inspire Pharmaceuticals Inc. (ISPH)

Kirin Brewery Co. Ltd. (Japan)

ND

Kirin gains rights to develop and commercialize Inspire's lung-disease diagnostic adjunct product in 21 Asian countries and regions; Inspire will receive an up-front payment in cash, plus milestones and royalties

Isis Pharmaceuticals Inc. (ISIP)

Coley Pharmaceutical Group

$10.7

Coley acquired patents covering immune stimulatory and modulatory phosphorothioate oligonucleotide technology

Labopharm Inc.

Aventis SA (France; NYSE:AVE)

ND

Labopharm will develop two new formulations of a marketed Aventis product

Lexicon Genetics Inc. (LEXG)

Bristol-Myers Squibb Co. (NYSE:BMY)

$15-$25

Lexicon provides a database access license for Bristol-Myers' target validation program

Maxygen (MAXY)

Pfizer Inc. (NYSE:PFE)

ND

Companies signed a follow-on agreement to 5/98 deal under which Maxygen usess its MolecularBreeding directed molecular evolution technologies to improve the selectivity of a biosynthetic pathway essential to the manufacture of a Pfizer drug

Novavax Inc. (AMEX:NOX) and the National Institutes of Health

SmithKline Beecham plc (UK; NYSE:SBH)

ND

SmithKline licenses rights to recombinant hepatitis E virus clones and antigen production technology from the NIH

Peptide Therapeutics Group plc (UK; LSE:PTE)

Baxter International Inc. (NYSE:BAX)

$200

Peptide will manufacture components of Baxter's vaccines at its facility in Canton, Mass.; Baxter licensed to Peptide rights to use its technology for for production of Japanese encephalitis and West Nile virus vaccines; Baxter also gains an option to be Peptide's marketing partner for Arilvax in the U.S.; Baxter committed to purchase 21.4M shares at an average price of 130p (US$1.87) per share in four tranches stretching to 2003; Peptide will receive manufacturing fees on a cost-plus basis, plus royalties, beginning in 2004; total potential revenues to Peptide could hit $200M by 2010

Pharmacopeia Inc. (PCOP)

Schering AG (Germany)

ND

A new research collaboration will focus on chemical optimization of lead compounds identified by Pharmacopeia in its lead discovery services agreement signed with Schering 10/98

PharmaNetics Inc.

Aventis Pharmaceuticals Inc. (France; NYSE:AVE)

$5

Companies signed five-year agreement for development and commercialization of a new diagnostic test calibrated for optimal response to Aventis' Lovenox (enoxaparin)

Protein Design Labs Inc. (PDLI)

Eli Lilly and Co. (NYSE:LLY)

1.36

PDL will humanize one or more murine antibodies to a single target for Lilly, in exchange for an up-front signing fee of $1.36M, milestones, maintenance fees and royalties

Proteome Inc.

Merck & Co. (NYSE:MRK)

ND

Proteome Inc. expanded its existing agreement with Merck to include new databases, the Human Proteome Survey Database and the G Protein-Coupler Receptor Proteome Database

Sangamo BioSciences Inc. (SGMO)

Merck & Co. Inc. (NYSE:MRK)

ND

Sangamo will provide Universal GeneTools to Merck for internal use

Symyx Technologies (SMMX)

Dow Chemical Co. (NYSE: DOW)

ND

The companies entered into a licensing agreement to develop catalysts for manufacturing of advanced pharmaceutical intermediates; Dow will fund the research effort, make payments upon technical success and commercialization and have exclusive rights to use the catalysts in their manufacturing process

Trega Biosciences Inc. (TRGA)

Aventis Pharma AG (unit of Aventis SA; France; NYSE:AVE)

ND

Aventis took an initial license to Trega's iDEA predictive model for drug absorption; license is Trega's 8th for the technology

Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

Access Pharmaceuticals Inc. (AMEX:AKC)

Laboratorios Dr. Esteve SA (Spain) and affiliate Isdin SA

ND

Under extension of previous agreement for amlexanox paste, Esteve exclusively licensed OraRinse, amlexanox cream and amlexanox gel for marketing in Portugal, Spain and Greece; Access will receive up-front and milestone payments, plus a percentage of sales for supplying the product; in addition, Esteve will make an equity investment in Access and provide funding for European clinical research

Active Biotech AB (Sweden; ACTIB)

Aventis Pasteur (unit of Aventis SA; France; NYSE:AVE)

ND

Aventis Pasteur will assume responsibility for marketing, sales and distribution of Active Biotech's drinkable cholera vaccine, SBL cholera vaccine, for all countries worldwide outside the U.S. and Europe

Active Biotech AB (Sweden; ACTIB)

SmithKline Beecham plc (UK; NYSE:SBH)

ND

Active Biotech reacquired rights for the ETEC vaccine project, now in Phase III trials, and the SBL cholera vaccine; SmithKline's pediatric vaccines, currently sold by Active Biotech through SBL Vaccin, will be transferred to the Nordic organization of SmithKline in 1/01

Anadys Pharmaceuticals inc.

Pharmacia Corp. (NYSE:PHA)

ND

Pharmacia obtained a non-exclusive license to Anadys' GATE (Genetics Assisted Target Evaluation) technology, for use in the discovery and validation of targets for antifungal drugs; Anadys will receive technology licensing fees and research payments

Atrix Laboratories Inc. (ATRX)

Pfizer Inc. (NYSE:PFE)

$5

Companies signed a research and worldwide licensing agreement providing Pfizer with access to Atrix's drug-delivery systems for development of new products; Pfizer will fund development and commercialization, and has rights to market products that emerge; Atrix retains manufacturing rights and will receive royalties on product sales; Pfizer made an initial $5M investment in Atrix

Boston Life Sciences Inc. (BLSI)

MDS Nordion Inc. (unit of MDS Inc.; Canada; TSE:MDS)

ND

MDS will provide pre-marketing supplies of Altropane, Boston Life's diagnostic agent for Parkinson's disease and attention deficit disorder; MDS will also manufacture the product for the commercial market if and when Altropane is approved

CollaGenex Pharmaceuticals Inc. (CGPI)

Taro International Ltd. (Israel)

ND

Taro will market CollaGenex's Periostat (for periodontal disease) in Israel; Taro will pay milestones associated with regulatory approvals and will purchase Periostat from CollaGenex

CollaGenex Pharmaceuticals Inc. (CGPI)

Showa Yakuhin Kako Co. Ltd. (Japan)

ND

Showa gains exclusive marketing rights in Japan, with an option to extend rights to other countries in Southeast Asia

Corixa Corp. (CRXA)

Medicis Pharmaceutical Corp. (NYSE:MRX)

$108

Medicis gains exclusive U.S. and Canadian rights to PVAC, a psoriasis immunotherapeutic product; Corixa will receive an up-front fee of $17M and potential milestones of up to $90M, plus potential royalties and manufacturing fees

Diversa Corp. (DVSA)

Celanese Ltd. (NYSE:CZ)

ND

Evaluation project to discover and develop microorganisms capable of producing chemical products at rates substantially higher than traditional microbial strains

Elan Corp. plc (Ireland; NYSE:ELN)

Pharmacia Corp. (NYSE:PHA)

ND

Research collaboration to find small-molecule inhibitors of beta-secretase for the treatment of Alzheimer's disease; companies will pool scientific resources and intellectual property, and share all associated costs and revenues

Entelos Inc.

AstraZeneca (UK; NYSE:AZN)

ND

AstraZeneca gains access to the Entelos Obesity PhysioLab, a disease simulation system

GeneData AG (Switzerland)

Pharmceuticals Group of Altana AG -- Byk Gulden (Germany)

ND

GeneData will provide access to its bioinformatics platform and will assist in analysis of functional genomics data

Genetronics Biomedical Inc. (AMEX:GEB)

Johnson & Johnson Research Pty. Ltd. (Australia)

ND

Collaboration to explore feasibility of using electroporation, Genetronics' platform technology, to deliver nucleic acid materials into tumors in vivo

GLYCODesign Inc.

Leo Pharmaceuticals Products Ltd. (Denmark)

ND

Companies formed a joint venture to develop cardiovascular drugs; companies will share equally costs of preclinical and initial clinical development up to the start of Phase II trials; Leo has an exclusive option to commercialize drug candidates in Europe

GPC Biotech AG (Germany; NeuerMarkt:GPC)

Bayer AG (Germany; DAX:BAY)

ND

GPC will perform compound mode-of-action studies for 50 Bayer antibacterial candidates using its Reverse Genomics technology platform

Incyte Genomics Inc. (INCY)

Bio-Active Co. Ltd. (Thailand), BioCat GmbH (Germany), Biomedical Sciences (Korea), B&L Systems (Holland), BS Company for Export & Import (Egypt), Cambridge Bioscience (UK), Genasia Scientifics Inc. (Taiwan), Integrated Sciences Pty Ltd. (Australia), Intermedica (Sweden), Izasa SA (Spain), Jingmei Biotech Co. Ltd. (China), Krabo Industries (Japan), LGC do Brasil (Brazil), M-Medical srl (Italy), Ornat Biochemicals & Laboratory Equipment Ltd. (Israel), Proteigene (France), Research Instruments (Singapore), Shanghai Sinroad Bioengineering Co. (China), and VWR Scientific Products (U.S.)

Incyte signed 19 distribution agreements allowing various companies to market, sell and distribute Incyte's clone reagent sets and gene-based research tools and services

Isis Pharmaceuticals Inc. (GeneTrove division; ISIP)

The R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson; NYSE:JNJ)

ND

GeneTrove will use antisense technology to validate and study PRI gene targets

Labopharm Inc. (Canada; TSE:DDS)

Aventis Pharmaceuticals Inc. (unit of Aventis SA; France; NYSE:AVE)

ND

Companies signed a feasibility and formulation agreement for use of Labopharm's controlled-release technology, Contramid; agreement calls for development of two new formulations of an undisclosed “top selling“ product

Lexicon Genetics Inc. (LEXG)

Oriental Yeast Co. (Japan)

ND

Collaboration to develop a web interface in the Japanese language that will allow researchers to access Lexicon's OmniBank library of knockout mouse clones

Maxim Pharmaceuticals Inc. (MAXM)

F. Hoffmann-La Roche Ltd. (Switzerland)

ND

Companies entered a Phase III development agreement for combination tehrapy for cancer and hepatitis C employing Maxim's Maxamine and Pegasys, Roche's pegylated interferon-alpha agent; Roche will shoulder most of the clinical trial responsibilities and costs, but each company will retain marketing responsibilities and revenues for its respective drug

MediChem

AstraZeneca (UK; NYSE:AZN)

ND

Companies renewed research collaboration for 12 months

NPS Allelix Corp. (subsidiary of NPS Pharmaceuticals Inc.; NPSP)

Forest Laboratories Inc. (NYSE:FRX)

ND

Forest gains worldwide marketing rights to ALX-0646, a drug for migraine headache

PPL Therapeutics Inc. (UK; LSE:PTH)

Bayer Corp. (unit of Bayer AG; Germany; DAX:BAY)

$40

Collaboration for the development of recombinant alpha-1 antitrypsin produced in transgenic mammals; Bayer will be responsible for clinical trials and marketing; PPL will handle manufacturing; Bayer will pay milestones of up to $25M, purchase $15M in PPL stock, and pay royalties and manufacturing fees if a product is commercialized

Rigel Inc.

Novartis Pharma AG (Switzerland; NYSE:NVS)

ND

Companies entered their third collaboration, focused on identifying drug targets for severe respiratory diseases such as asthma and chronic obstructive pulmonary disease; the initiation of the project triggeres a cash payment to Rigel, which will also receive milestone and royalty payments; Novartis has worldwide rights to development and market products

Spotfire Inc.

Eli Lilly and Co. (NYSE:LLY)

ND

Lilly will implement Spotfire's suite of Spotfire.net decision analytics software solutions at its R&D sites in the U.S. and Europe

STC Technologies Inc.

Meridian Diagnostics Inc. (KITS)

ND

Companies entered a multi-year, multi-million-dollar exclusive research and supply agreement to develop, manufacture and sell point of care tests for rapid detection of parasites, gastrointestinal and upper respiratory diseases

Xenogen Corp.

Novartis Research Foundation (unit of Novartis AG; NYSE:NVS)

ND

Three-year, multimillion-dollar agreement for use of Xenogen's real-time in vivo imaging technology for preclinical drug development studies

Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

3-Dimensional Pharmaceuticals Inc. (DDDP)

Bristol-Myers Squibb Co. (NYSE:BMY)

$37.9

BMS gains access to access to 3DP's small-molecule drug discovery technology and G protein-coupled receptor technology, including Proteomica database; 3DP will receive up-front licensing and technology access fees of $23.5M, plus committed research funding of $14.4M, as well as payments for the purchase of screening workstations; BMS gains exclusive worldwide rights to compounds discovered or developed and access to various elements of 3DP's platforms; in December, the companies modified the agreement with the return of $4.5M in up-front fees, the increase of BMS' commitment to purchase ThermoFluour workstations from three to seven, and the removal of nonexclusive licenses to 3DP's protein expression/refolding technology and GPCR structural genomics database

Affymetrix Inc. (AFFX)

The R.W. Johnson Pharmaceutical Research Institute and the Janssen Research Foundation (units of Johnson & Johnson; NYSE:JNJ)

ND

J&J affiliates signed an EasyAccess Silver agreement for broad access to Affymetrix's standard and custom GeneChip arrays, instrumentation and software to monitor gene expression; entities have also taken a license to use nucleic acid arrays for use in their pharmaceutical research and development activities

AltaRex Corp. (Canada; TSE:AXO)

Medison Pharma Ltd. (Israel)

ND

The companies established a joint venture to commercialize OvaRex and other anti-idiotype induction therapy cancer products in Israel and the Middle East; Medison is responsible for local drug development costs; Medison will conduct distribution and marketing; resulting profits will be distributed equally; Medison's principals will make a nominal equity investment in AltaRex

Celera Genomics (NYSE:CRA)

American Home Products Corp. (NYSE:AHP)

ND

AHP acquired a database subscription and license option; database deal provides access to Celera's suite of genomic databases and includes bioinformatics systems and analytical tools; AHP also receives an option to obtain a non-exclusive license to certain other Celera intellectual property

Cell Pathways Inc. (CLPA)

Aventis Pharmaceuticals (France; NYSE:AVE)

ND

Cell Pathways obtained rights from Aventis to market Nilandron (nilutamide) to urologists in the U.S. and Puerto Rico for use in patients with prostate cancer

Cell Pathways Inc. (CLPA)

Glaxo Wellcome Inc. (unit of Glaxo Wellcome plc; UK; NYSE:GLX)

ND

Companies will cooperate to fund a clinical trial of a combination of Cell Pathways' Aptosyn (exisulind) and Glaxo's Navelbine (vinorelbine tartrate injection) as a first-line treatment for elderly patients with non-small-cell lung cancer; each company retains rights to its respective drug

Cell Pathways Inc. (CLPA)

Paladin Labs (TSE:PLB)

ND

Paladin gains exclusive marketing rights in Canada to Aptosyn (initial indication of precancerous colon polymps in patients with familial andenomatous polyposis)

Chiron Corp. (CHIR)

Aventis Pasteur (unit of Aventis SA; France; NYSE:AVE)

ND

Aventis will assist Chiron in marketing and sales efforts for meningococcal C and flu vaccines in the UK and Ireland; Aventis will distribute, market and sell (co-market) Menjugate under its own label in the rest of Europe

CV Therapeutics Inc. (CVTX)

Fujisawa Healthcare Inc. (Japan)

$34

Collaboration to develop second-generation pharmacologic cardiac stress agents, including CVT-3146, a short-acting selective A2A adenosine receptor agonist, and a backup compound; CV will receive $10M for prepayment of a development milestone and an equity stock purchase, and may receive up to an additional $24M in milestone-based cash; Fujisawa will reimburse CV for 75% of development costs and will pay royalties if CVT-3146 is approved

Discovery Therapeutics Inc. (DPII)

Bayer AG (Germany; DAX:BAY)

ND

Discovery acquired two anti-inflammatory drug candidates from Bayer; one is a clinical-stage drug for glomerulonephritis; agreement includes license and milestone fees and royalties

GeneFormatics Inc.

Bristol-Myers Squibb Co. (NYSE:BMY)

ND

Collaboration is the first step toward a more comprehensive agreement for application of GeneFormatics' Fuzzy Functional Form technology to elucidate function of proteins encoded by selected genes

Genome Therapeutics Corp. (GENE)

Schering-Plough Corp. (NYSE:SGP)

ND

Companies extended through 9/01 a 1995 collaboration to develop anti-infectives for drug resistant bacteria

Genomics Collaborative Inc.

Qiagen Genomics Inc. (QGENF)

ND

Companies will offer integrated solution combining GCI's sample repository and database services with Qiagen's single nucleotide polymorphism genotyping services

Karo Bio (Sweden; SSE:KARO)

Bristol-Myers Squibb Co. (NYSE:BMY)

ND

Companies extended 10/97 agreement for development of drugs for obesity, hypercholesterolemia and insulin resistance that act selectively on the thyroid hormone receptor

Incyte Genomics Inc. (INCY)

American Home Products Corp. (NYSE:AHP)

ND

AHP gains access to Incyte's suite of genomic databases; Incyte could receive milestones and royalties on sales of products developed with Incyte technology and database information

Insmed Inc. (INSM)

Taisho Pharmaceutical Co. Ltd. (Japan)

$32

Taisho will provide $32M in the form of license fees, milestones and an equity investment, and will also fund 20% of development costs for North America and Europe; in exchange, Taisho receives marketing rights to Insmed's INS-1 for the treatment of Type II diabetes and polycystic ovary syndrome in Japan and other Asian countries

MedImmune Inc. (MEDI)

SmithKline Beecham plc (UK; NYSE:SBH)

$30

SmithKline will pay up-front and future milestone payments of more than $30M, plus royalties, to license MedImmune's Streptococcus pneumoniae vaccine technology; SmithKline is responsible for development

Millennium Predictive Medicine Inc. (subsidiary of Millennium Pharmaceuticals Inc.; MLNM)

Becton Dickinson and Co. (NYSE:BDX)

ND

Collaboration on diagnostic markers associated with colon cancer; includes option for a commercial license

Neurocrine Biosciences Inc. (NBIX)

Taisho Pharmaceutical Co. Ltd. (Japan)

$45

Companies finalized 1/00 agreement providing Taisho exclusive rights to NBI-6024 for diabetes in Europe and Asia; Neurocrine could receive $45M in licensing and option payments, milestones and development reimbursements, plus royalties

Orchid BioSciences Inc. (ORCH)

Bristol-Myers Squibb Co. (NYSE:BMY)

ND

Multi-year agreement under which BMS will purchase Orchid's SNPstream 25K solution for industrial-scale scoring of single nucleotide polymorphisms; BMS will make an upfront payment to Orchid and will pay fees for SNPware consumables

PE Biosystems (NYSE: PEB)

Roche (Switzerland)

ND

Agreement allows both companies to develop and market products for all potential uses of polymerase chain reaction technology

Pharmacopeia Inc. (PCOP)

Pharmacia Corp. (NYSE:PHA)

ND

Pharmacia ended two-year research collaboration six months early, but replaced it with a new agreement under which Pharmacia will continue to develop lead compounds discovered under the original collaboration

SangStat Medical Corp. (SANG)

Novartis Pharmaceuticals Corp. (Switzerland; NYSE:NVS)

ND

Companies settled patent infringement litigation regarding SangCya Oral Solution, a liquid oral cyclosporine product similar to Novartis' Neoral; the companies signed a license agreement

SkyePharma plc (UK; LSE:SKP)

Paladin Labs Inc. (TSE:PLB)

$1

Paladin gains exclusive rights to market DepoCyt (injectable, sustained-release cytarabine) in Canada; terms include an up-front payment of $1M to SkyePharma, plus additional milestones and a significant share of future revenues from the product

Texas Biotechnology Corp. (AMEX:TXB)

Schering-Plough Corp. (NYSE:SGP)

$87

Schering-Plough obtains exclusive worldwide rights to develop, manufacture and market all compounds from Texas Biotech's library of VLA-4 antagonists, which have shown promise for asthma, as well as rights to a second integrin antagonist; Texas Biotech could receive $87M before royalties

Trega Biosciences Inc. (TRGA)

F. Hoffmann-La Roche Ltd. (Switzerland)

ND

Following a successful validation study, Roche licensed Trega's IDEA predictive model for drug absorption for use in drug discovery

Vical Inc. (VICL)

Aventis SA (France; NYSE:AVE)

$1.5

Aventis licensed rights to use Vical's naked DNA gene transfer technology to deliver a growth factor; Vical received $1.5M up front and could receive milestones and royalties

Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

Access Pharmaceuticals Inc. (AMEX:AKC)

Mipharm SpA (Italy)

ND

Mipharm acquires marketing and manufacturing rights to the canker sore drug amlexanox in Italy, Switzerland, Turkey and Lebanon

Affymetrix Inc. (AFFX)

Merck & Co. Inc. (MRK)

ND

Merck gains broad access to standard and custom GeneChip arrays, instrumentation and software to monitor gene expression; Merck also obtained a license to produce and use expression monitoring arrays for internal research efforts

Athersys Inc.

Covance Biotechnology Services Inc.

ND

Covance will manufacture an Athersys therapeutic protein for preclinical and clinical studies

Alkermes (ALKS)

Glaxo Wellcome plc (UK; NYSE:GLX)

ND

After completing feasibility studies, Glaxo obtained a broad license to Alkermes' AIR pulmonary delivery technology for use in the development of products for respiratory diseases

AltaRex Corp. (Canada; TSE:AXO)

Genesis Pharma SA (Greece)

ND

Companies signed memorandum of understanding to establish a 50-50 joint venture to commercialize OvaRex (for ovarian cancer) and similar cancer antibody products in Greece, Turkey, Cyprus and the Balkans

Battelle Pulmonary Therapeutics Inc. (for-profit subsidiary of the Battelle Memorial Institute)

Abbott Laboratories (NYSE:ABT)

ND

Abbott will license new products and drug delivery technologies to develop therapies for a variety of respiratory diseases

Bio-Technology General Corp.

DePuy Orthopaedics Inc. (unit of Johnson & Johnson; NYSE:JNJ)

ND

DePuy gains exclusive rights to TG's BioHy high-molecular-weight sodium hyaluronate product (for the treatment of pain associated with osteoarthritis of the knee) in all countries worldwide except Japan and Israel

Cellomics Inc.

Beckman Coulter Inc. (NSYE:BEC)

ND

Long-term relationship to market Cellomics' High Content Screening technologies; companies also established a technology collaboration in mutual fields of interest

Cel-Sci Corp. (AMEX:CVM)

Bio Science Contract Production Corp.

ND

Bio Science will manufacture Cel-Sci's immunotherapy cancer product Multikine, now in Phase II trials

Cetek Corp.

Schering-Plough Research Institute (unit of Schering-Plough Corp.; NYSE:SGP)

ND

Cetek will develop assays for Schering targets and screen them against Schering libraries; agreement follows a pilot project

CollaGenex Pharmaceuticals Inc. (CGPI)

Willvonseder & Marchesani GmbH & Co. KG (Austria) and Karr Dental Ltd. (Switzerland)

ND

W&M will market CollaGenex's Periostat in Austria, and Karr will market the product in Switzerland

CuraGen Corp. (CRGN)

Ono Pharmaceutical Co. Ltd. (Japan)

ND

Pharmacogenomic collaboration; use of CuraGen's functional genomics platform to perform molecular toxicology studies and help Ono select drug candidates

Dura Pharmaceuticals Inc. (DURA)

Allergan Inc. (NYSE:AGN)

ND

Expansion of 2/99 marketing agreement allowing Dura to market Allergan's Ocuflox (ofloxacin ophthalmic solution) 0.3% for bacterial conjuctivitis and corneal ulcers

Emisphere Technologies Inc. (EMIS)

Eli Lilly and Co. (NYSE:LLY)

$2

Follow-on agreement to 1997 multi-year research and option deal; companies will develop oral formulations of Forteo (recombinant parathyroid hormone) and Humatrope (somatropin); new agreement provides additional R&D funding, plus Emisphere receives a $2M milestone under previous deal

Emisphere Technologies Inc. (EMIS)

DuPont Pharmaceuticals Co. (unit of DuPont; NYSE:DD)

ND

Companies agreed to terms of a development and marketing agreement for solid oral dosage formulations of heparin and low-molecular-weight heparin using Emisphere's technology; Emisphere will receive up-front fees, milestones and royalties

Eos Biotechnology Inc.

Aventis Pasteur (unit of Aventis SA; France; NYSE:AVE)

ND

Alliance will use Eos' genomics approach to find new targets for vaccines; Aventis gains an exclusive license in return for an up-front payment and R&D funding, plus milestones on any developed products

Exelixis Inc. (EXEL)

Bristol-Myers Squibb Co. (NYSE:BMY)

ND

Expansion of 9/99 agreement under which Exelixis identifies the mechanism of action of BMS compounds

GeneFormatics Inc.

Schering-Plough Research Institute (unit of Schering-Plough Corp.; NYSE:SGP)

ND

GeneFormatics will apply its Fuzzy Functional Form technology to gene sequences of interest to elucidate the function of the encoded proteins

Genome Therapeutics Corp. (GENE)

Schering-Plough Corp. (NYSE:SGP)

ND

Genome Therapeutics will provide contract DNA sequencing in support of Schering-Plough drug discovery efforts

Icos Corp. (ICOS)

Abbott Laboratories (NYSE:ABT)

ND

Icos acquired rights to all LFA-1 antagonists discovered under the companies' 1995 agreement; previously, Icos had marketing rights only for cancer; Abbott will receive royalties on any marketed products

Idec Pharmaceuticals Corp. (IDPH)

Taisho Pharmaceuticals Co. Ltd. (Japan)

$35

Idec will develop humanized monoclonal antibodies against macrophage migration inhibitory factor for the treatment of inflammatory and autoimmune diseases; Idec will have exclusive rights in the Americas; Taisho will have exclusive rights elsewhere

Incyte Genomics Inc. (INCY)

Eli Lilly and Co. (NYSE:LLY)

ND

Companies expanded agreement for development of therapeutic proteins; Lilly will obtain options to license multiple therapeutic protein patents from Incyte

Incyte Genomics Inc. (INCY)

Aventis Pharma (unit of Aventis SA; France; NYSE:AVE)

ND

Expansion of existing agreement to include access to Incyte's custom single nucleotide polymorphism program

LifeSpan BioSciences Inc.

Novartis Research Foundation (unit of Novartis AG; Switzerland)

ND

Novartis is the initial subscriber to LifeSpan's database of information on G protein-coupled receptors

Millennium Pharmaceuticals Inc. (MLNM)

Aventis Pharma (unit of Aventis SA; France; NYSE:AVE)

$450

Multifaceted agreement under which Millennium and Aventis will collaborate on drugs for inflammatory disorders, jointly develop new drug discovery technologies and transfer key elements of Millennium's technology platform to Aventis; Aventis will invest $250M in Millennium equity, $150M of which is due at closing; Aventis will pay $200M over five years for access to Millennium's drug discovery technologies; companies will share costs and profits for collaborative drug development in North America; outside North America, Aventis will develop and market products and pay royalties to Millennium

Millennium Pharmaceuticals Inc. (MLNM)

Eli Lilly and Co. (NYSE:LLY)

ND

Extension of cardiovascular disease research agreement dating from 10/95 through at least 10/01, at which time Lilly has the option to extend for up to two additional years

Millennium Pharmaceuticals Inc. (MLNM)

Biacore AB (Sweden)

ND

Three-year collaboration to co-develop a new generation of surface plasmon resonance array chip technology for use in drug discovery

Modex Therapeutics Ltd. (France)

Novartis Pharma AG (Switzerland)

ND

Companies will apply Modex's Encapsulated Cell Therapy system (implanted, encapsulated human cells genetically engineered to produce therapeutic proteins) to develop treatments for solid tumors

NaPro BioTherapeutics Inc. (NPRO)

Abbott Laboratories (NYSE:ABT)

ND

Companies expanded 7/99 agreement for NaPro's formulation of paclitaxel to provide increased flexibility for development and marketing in the U.S.

NaPro BioTherapeutics Inc. (NPRO)

F.H. Faulding & Co. Ltd.

ND

Expanded existing marketing agreement for NaPro's paclitaxel to include all of Central America, South America and Mexico, as well as South Africa and additional territories in Southeast Asia and Middle East

Neurobiological Technologies Inc. (NTII)

Merz + Co. (Germany) and Forest Laboratories (NYSE:FRX)

$7.7

Merz signed a new U.S. development and marketing agreement with Forest for NTI's Memantine for Alzheimer's disease, neuropathic pain and other central nervous system indications; NTI will receive front-end milestones of $7.7M, plus additional royalties under a 4/98 agreement with Merz

OSI Pharmaceuticals Inc. (OSIP)

Pfizer Inc. (NYSE:PFE)

ND

Pfizer granted all development and marketing rights to the EGFR inhibitor CP-358,774 (OSI-774) to OSI; the compound is the most advanced arising from their existing collaboration and is currently in Phase II trials; Pfizer made the move to meet Federal Trade Commission requirements resulting from the agency's review of the company's plan to merge with Warner-Lambert Co. (which has a similar product in development)

Oxford Biomedica plc (UK; LSE:OXB)

Aventis Pharmaceuticals Inc. (unit of Aventis SA; France; NYSE:AVE)

ND

Expanded the scope of 12/98 agreement to include Oxford's LentiVector gene delivery vectors for cardiovascular gene therapy; Aventis also exercised an option for an additional angiogenic gene

Progen Industries Ltd. (Australia; PGLAF)

Medigen Biotechnology Corp. (Taiwanese company created for this collaboration)

A$11 (US$6.3)

Medigen will purchase A$11M (US$6.3M) in Progen equity, and will conduct several trials of PI-88, a cancer and cardiovascular drug; Medigen will receive 15% of future PI-88 revenues in those indications

QLT PhotoTherapeutics Inc. (Canada; QLTI)

Axcan Pharma Inc. (Canada; AXCN)

$40.5

QLT sold worldwide rights to the photodynamic cancer therapy Photofrin to Axcan for an initial cash payment of $2.5M, 1.3M common shares of Axcan, and $13.5M worth of preferred shares

Sangamo BioSciences Inc. (SGMO)

The R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson; NYSE:JNJ)

ND

Collaboration to develop small-molecule screening platform using Sangamo's zinc finger DNA binding proteins

Third Wave Technologies Inc.

Novartis Pharmaceuticals Corp. (unit of Novartis AG; Switzerland)

ND

Third Wave will develop a high-density panel of 10,000 single nucleotide polymorphism assays spaced across the human genome; the panel will use Third Wave's Invader technology to detect SNPs released by The SNP Consortium on 5/1/00; the agreement allows Third Wave to commercialize the panel to third parties

Third Wave Technologies Inc.

SmithKline Beecham Biologicals (unit of SmithKline Beecham; UK; NYSE:SBH)

ND

SmithKline will evaluate Third Wave's Invader assays for genotyping and gene expression, with an eye toward using the system to report results in therapeutic vaccine applications

Tripos Inc. (TRPS)

Lipha SA (France; subsidiary of Merck KGaA)

ND

One-year, “multimillion-dollar“ agreement to use Tripos' compound library design technology to discover drugs for the treatment of metabolic and other associated diseases

Tularik Inc. (TLRK)

Japan Tobacco Inc. (Japan)

$75

Tularik will form a subsidiary for the project to develop therapies for metabolic diseases; Tularik receives $25M up front, plus research and other payments in excess of $50M over five years

Unigene Laboratories Inc. (OTC BB:UGNE)

Sijiazhuang Pharmaceutical Group Company Ltd. (China)

ND

Companies established a joint venture to manufacture and distribute injectable and nasal calcitonin products for the treatment of osteoporosis in China and possibly other Asian markets

United Therapeutics Corp. (UTHR)

Toray Industries (Japan)

$23

United will pay $1M plus 0.2M shares of common stock (worth about $22M) for exclusive North American rights to develop and commercialize sustained-release formulations of the oral prostacyclin Beraprost for vascular and cardiovascular diseases; Toray also has an option to purchase an additional 0.5M shares and could receive $0.75M in milestones, plus a variable percentage of North American sales

United Therapeutics Corp. (UTHR)

Nova-Tex Ltd. (Israel)

ND

Nova-Tex will distribute United's pulmonary hypertension drug, Uniprost, in Israel

Vivus Inc. (VVUS)

Abbott Laboratories (NYSE:ABT)

ND

Abbott gains exclusive rights to market the erectile dysfunction products Muse (alprostadil) and Alibra in Europe, Japan, Australia, New Zealand and South and Central America; Abbott also has an option to co-develop and license future Vivus transurethral products for erectile dysfunction in these markets

Biotech Company

Pharma Company

Disclosed Potential Funding (M)

Details

Abgenix Inc. (ABGX)

SmithKline Beecham plc (UK; NYSE:SBH)

ND

Agreement to use Abgenix's XenoMouse technology to generate fully human monoclonal antibodies to an undisclosed target

Affymetrix Inc. (AFFX)

Procter & Gamble Co. (NYSE:PG)

ND

EasyAccess Silver agreement providing access to Affymetrix's GeneChip arrays and associated technology

Alliance Pharmaceutical Corp. (ALLP)

Baxter Healthcare Corp. (NYSE:BAX)

$50

Collaboration for the manufacturing, sale and distribution of Alliance's Oxygent in the U.S., Canada and Europe

Aurora Biosciences Corp. (ABSC)

The R.W. Johnson Pharmaceutical Research Institute and Janssen Research Foundation (units of Johnson & Johnson; NYSE:JNJ)

ND

Agreement to develop ion channel assays and for Aurora to provide access to its technologies

Axon Instruments Inc. (Australia; ASX:AXN)

AstraZeneca plc (UK)

ND

Collaboration to develop an automated higher-throughput electrophysiology system for drug screening

Axonyx Inc.

Ares-Serono (Switzerland)

$22.5

Agreement to license Axonyx's platform anti-amyloid peptide technology to Ares-Serono

Bio-Technology General Corp.

Abbott Laboratories (NYSE:ABT)

ND

Agreement to co-market Oxandrin in the U.S.

Corvas International Inc. (CVAS)

Schering-Plough Corp. (NYSE:SGP)

$2.5

Amended agreement on the development of synthetic antiviral compounds to treat and prevent hepatitis C; gives Schering-Plough exclusive license to technology and intellectual property related to hepatitis C drugs

CyDex Inc.

Bristol-Myers Squibb Co. (NYSE:BMY)

ND

Agreement for Bristol-Myers to use Captisol sulfobutylether beta-cyclodextrin drug delivery technology to develop a second compound

DuPont Pharmaceuticals Co. (unit of DuPont; NYSE:DD)

Kos Pharmaceuticals Inc. (KOSP)

$80

Alliance to develop and commercialize Nicostatin and explore additional opportunities in the cardiovascular and cholesterol management areas

Elitra Pharmaceuticals Inc.

LG Chemical Ltd.

$30

Agreement to collaborate on the discovery and development of antimicrobial drugs for up to five years

Genome Therapeutics Corp. (GENE)

Schering-Plough Corp. (NYSE:SGP)

$76

Extension of alliance to discover new therapeutics for treating asthma; extended through December 2001

HTS Biosystems Inc.

Ciencia Inc.

ND

Licensing and consulting agreements to develop high-throughput detection systems for pharmaceutical and genomics research markets

Hyseq Inc. (HYSQ)

Kirin Brewery Co. Ltd. (Japan)

ND

Expanded collaboration to include potential drug candidates discovered that are outside the original agreement's field of cell growth factors

Lark Technologies Inc. (OTC BB:LDNA)

Novartis Research Foundation (unit of Novartis AG; Switzerland; NYSE:NVS)

ND

Agreement for Lark to provide DNA sequencing services to support gene discovery efforts at Novartis

Ligand Pharmaceuticals Inc. (LGND)

Bristol-Myers Squibb Co. (NYSE:BMY)

$8.6

Collaborative research agreement focusing on the discovery, design and development of orally active compounds that selectively modulate the mineralocorticoid receptor

Medinox Inc.

Fuso Pharmaceutical Industries Ltd. (Japan)

ND

Collaboration to develop and market NOX-100 for sepsis and one additional indication in Japan

Microcide Pharmaceuticals Inc. (MCDE)

Daiichi Pharmaceutical Co. Ltd. (Japan)

ND

Research alliance to discover and develop inhibitors that will overcome the effect of efflux pumps in Pseudomonas aeruginosa

Molecular Biosystems Inc. (OTC BB:MBIO)

Mallinckrodt Inc. (NYSE:MKG)

ND

Restructured agreement giving Mallinckrodt full control of the Optison (ultrasound contrast agent) business, including responsibility for intellectual property disputes, clinical development, manufacturing and real estate

Myriad Genetics Inc. (MYGN)

Hitachi Ltd. (Japan)

$26

Strategic alliance based on Myriad's ProNet to expedite the discovery of novel protein-protein interactions for Japanese customers

Neose Technologies Inc. (NTEC)

Bristol-Myers Squibb Co. (NYSE:BMY)

$3.7

Expanded agreement to provide additional process development services under a collaboration to develop a commercial GMP manufacturing process for two therapeutic cancer vaccines

Nexell Therapeutics Inc. (NEXL)

Takara Shuzo Co. Ltd. (Japan)

ND

Strategic alliance allowing Takara to exclusively distribute Nexell cell therapy products in Japan, Korea, Taiwan and China

Paradigm Genetics Inc. (PDGM)

Monsanto Co. (unit of Pharmacia; NYSE:PHA)

ND

Expanded collaboration in the field of functional genomics, now including Renessen LLC as an affiliate

Protein Design Labs Inc. (PDLI)

Chugai Pharmaceutical Co. Ltd. (Japan)

$6.04

Agreement for license under PDL's antibody humanization patents for an undisclosed number of Chugai antibody targets

Protein Design Labs Inc. (PDLI)

Toagosei Co. Ltd. (Japan)

ND

Joint development agreement for an antibody, SMART Anti-VEGF, developed by Toagosei and humanized by PDL; to be developed as a treatment for cancer

ReNeuron (UK)

Novo Nordisk A/S (Denmark; NYSE:NVO)

ND

ReNeuron in-licensed a class of molecules affecting pain and inflammation signals; lead compound is ready for Phase II trials

RxKinetix Inc.

Elan Corp. plc (Ireland; NYSE:ELN)

$2.5

Licensing and collaborative alliance to develop compound formulations to treat oral mucositis

SkyePharma plc (UK; LSE:SKP)

Merck KGaA (Germany)

ND

Agreement to jointly develop an innovative formulation of a Merck compound based on the Geomatrix oral controlled-release technology

SkyePharma plc (UK; LSE:SKP)

Pfizer Inc. (NYSE:PFE)

ND

Second development agreement to use DepoFoam sustained-release injection technology to formulate a Pfizer compound

Trega Biosciences Inc. (TRGA)

Boehringer Ingelheim International GmbH (Germany)

ND

Expanded agreement for the custom synthesis of exclusive compound libraries

United Therapeutics Corp. (UTHR)

Grupo Ferrer Internacional SA (Spain)

ND

Strategic alliance for the distribution of Uniprost in Spain, France, Germany, Italy, Portugal, Greece and Belgium, as well as Mexico and all countries in Latin America

Vertex Pharmaceuticals Inc. (VRTX)

Novartis Pharma AG (Switzerland; NYSE:NVS)

$800

Alliance to discover, develop and commercialize eight small-molecule drugs directed at targets in the kinase protein family

Xenon Genetics Inc.

Warner-Lambert Co. (unit of Pfizer Inc.; NYSE:PFE)

$57.75

Collaboration agreement to identify, develop and commercialize products to treat low HDL cholesterol

Xoma Ltd. (XOMA)

Allergan (NYSE:AGN)

$11

Expansion of 6/99 collaboration worth up to $11M to develop ophthalmic anti-infective product; new agreement covers all formulations and all microbes; collaboration dissolved 11/00